Melbourne, Australia, 3 February, 2026 – Evinco Therapeutics is pleased to announce that Dr Jing Tee, Research Scientist will present a poster at the ANZ Biologics Festival 2026 in Melbourne (4-5 February), showcasing Evinco’s novel approach to addressing the significant unmet medical need in Alzheimer’s disease.

The poster titled, ‘Natural Killer cell-derived vesicles as novel immunotherapy for Alzheimer’s Disease’ will provide an introduction to Evinco Therapeutics, outline the ongoing challenges in treating Alzheimer’s Disease, and highlight emerging science supporting a neuro-immune therapeutic strategy. It will explore Evinco’s innovative work investigating the potential of natural killer (NK) cell-derived extracellular vesicles (EVs) as a new modality for the treatment of Alzheimer’s disease.

Alzheimer’s disease is one of the fastest-growing global health challenges, affecting tens of millions of patients worldwide and representing a multi-billion-dollar market. Despite recent approvals, current therapies offer limited disease modification, face safety concerns, and remain costly. There is a clear unmet need for safe, effective, and accessible treatments.

Evinco Therapeutics is developing a first-in-class, immune-derived therapy for Alzheimer’s disease. The company’s NK cell–derived EVs are to be delivered intranasally, a non-invasive approach designed to directly access the brain and overcome key limitations of current therapies. 

We look forward to engaging with attendees at Biologics 2026 and sharing progress on this exciting therapeutic approach.